Literature review of clinical cases and case series of interface keratitis following DALK
| Patients (n) | Age (years) | Microorganism isolated from specimens | Time to infection onset (day) | Donor rim culture | Time to positive donor rim culture report (day) | Medical treatment topical and /or systemic | Surgical treatment | Endophtha lmitis | Visual outcome (BSCVA Snellen) | Postoperative complications | |
| Panda et al 5 | 1 | 55 |
Rhodotorula sp (donor button+interface biopsy) | 5 | nr | nr | Topical natamycin 5% Amphotericin B 0.15% | Donor button exchange | No | nr | No |
| Fontana et al 6 | 1 | 30 |
Candida albicans
(donor button) | 28 | C. albicans | 5 | Topical amphotericin B (3 mg/mL) Liposomal amphotericin B (3 mg/kg) IV | Donor button exchange+interface amphotericin B (5 µg/0.1 mL) PK | No | 20/25 | No |
| Kanavi et al 7 | 2 | 21 |
Candida
glabrata
(donor button) | 60 | nr | nr | Topical amphotericin B, oral ketoconazole 400 mg once in a day | Interface irrigation with DM rupture PK | No | nr | No |
| 25 |
C. albicans
(donor button) | 75 | nr | nr | Natamycin 5%, oral ketaconazole 400 mg once in a day | PK | No | nr | No | ||
| Zarei-Ghanavati et al 8 | 1 | 35 |
Klebsiella pneumoniae
(donor button) | 2 | Klebsiella pneumoniae | 2 | Topical vancomycin (50 mg/mL), ceftazidime (50 mg/mL) | PK | No | 20/20 | No |
| Caretti et al 9 | 1 | 21 | Actinomyces species (donor button) | 6 | nr | nr | Topical ofloxacin 0.3%, betamethasone 0.13%+chloramphenicol 0.25%, amphotericin B | PK PK graft exchange | No | 20/25 | No |
| Bahadir et al 10 | 1 | 23 | Candida species (donor button) | 30 | Not performed | na | Topical amphotericin B (5 µg/mL), cefuroxime (1 mg/mL) Liposomal amphotericin B (3 mg/mL) IV Oral itraconazole 200 mg OD | Interface irrigation DM rupture PK | No | nr | No |
| Sedaghatet al 11 | 1 | 18 |
C. albicans
(irrigation liquid) | 120 | Negative | nr | Topical ceftazidime (50 mg/mL), vancomycin (50 mg/mL), natamycin 5% | Interface irrigation (amphotericin B 0.15%) DM rupture | No | 20/30 | No |
| Wesse et al 12 | 1 | 39 | Candida orthopsilosis (donor button) | 5 | Yeasts | 6 | Topical voriconazole, oral voriconazole 400 mg two times a day | Interface irrigation voriconazole (0.25 mg/mL)+amphotericin B (0.5 mg/mL) PK | No | 20/630 | No |
| Murthy et al 13 | 1 | 26 | Atypical Mycobacterium (donor button) | 90 | nr | nr | Topical amikacin 2.5% | Donor button exchange PK | No | 20/40 | No |
| Le et al 14 | 1 | 31 |
C. glabrata
(donor button) | 6 | Medium culture negative Donor rim culture not performed | nr | Topical levofloxacin 0.5%, fluconazole 0.5% | Interface irrigation cefuroxime 5%+fluconazole (0.8 g/L) donor button exchange PK | No | 20/40 | No |
| Kodavoor15 | 1 | 32N | Negative | 90 | nr | nr | Topical voriconazole, natamycin, oral itraconazole 100 mg twice a day | None | No | 20/80 | Leucomatous scar |
BSCVA, best-spectacle corrected visual acuity; DM, Descemet membrane; PK, penetrating keratoplasty; na, not applicable; nr, not reported.